1. Home
  2. FSP vs MOLN Comparison

FSP vs MOLN Comparison

Compare FSP & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

HOLD

Current Price

$0.40

Market Cap

48.2M

Sector

Real Estate

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.29

Market Cap

170.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FSP
MOLN
Founded
1981
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
48.2M
170.5M
IPO Year
2001
2021

Fundamental Metrics

Financial Performance
Metric
FSP
MOLN
Price
$0.40
$4.29
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
365.6K
1.3K
Earning Date
04-28-2026
05-12-2026
Dividend Yield
6.34%
N/A
EPS Growth
15.69
N/A
EPS
N/A
N/A
Revenue
$107,162,000.00
N/A
Revenue This Year
$17.91
N/A
Revenue Next Year
N/A
$374.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$3.53
52 Week High
$1.73
$5.36

Technical Indicators

Market Signals
Indicator
FSP
MOLN
Relative Strength Index (RSI) 37.17 51.88
Support Level N/A $4.13
Resistance Level $0.51 $4.30
Average True Range (ATR) 0.03 0.07
MACD -0.00 0.01
Stochastic Oscillator 4.36 31.25

Price Performance

Historical Comparison
FSP
MOLN

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: